.
Tysabri cut the risk of disability progression by 42%, according to the results of two phase III trials and one safety evaluation study..[Read More]The results also showed that treatment with Tysabri, whose generic name is natalizumab, led to a 68% reduction in the annualized relapse rate compared with the use of a placebo. A second trial studying Tysabri's use with Avonex, another multiple sclerosis treatment sold by Biogen, reported that the drug had a significant effect on disability progression, relapse rate and brain lesions compared with Avonex alone